![Chad Decker](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
Chad Decker currently works as a Chief Operating Officer at Alphazyme LLC.
Chad Decker active positions
Companies | Position | Start |
---|---|---|
Alphazyme LLC
![]() Alphazyme LLC Miscellaneous Commercial ServicesCommercial Services Part of Maravai Lifesciences Holdings, Inc., Alphazyme LLC is a company that specializes in the development and production of custom molecular biology enzymes at an industrial scale. The company is based in Jupiter, FL. The company collaborates with manufacturers of nucleic acid synthesis and detection platforms to produce high-quality and affordable enzymes for the growing markets of custom DNA and RNA molecules, genomic medicines, and genetic analysis. Alphazyme's mission is to be the world's premier partner for industrial-scale molecular biology enzymes. The company was founded by Christopher Benoit, who has been the CEO since incorporation. Alphazyme was acquired by Maravai Lifesciences Holdings, Inc. on February 22, 2023, for $145 million. | Chief Operating Officer | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
Alphazyme LLC
![]() Alphazyme LLC Miscellaneous Commercial ServicesCommercial Services Part of Maravai Lifesciences Holdings, Inc., Alphazyme LLC is a company that specializes in the development and production of custom molecular biology enzymes at an industrial scale. The company is based in Jupiter, FL. The company collaborates with manufacturers of nucleic acid synthesis and detection platforms to produce high-quality and affordable enzymes for the growing markets of custom DNA and RNA molecules, genomic medicines, and genetic analysis. Alphazyme's mission is to be the world's premier partner for industrial-scale molecular biology enzymes. The company was founded by Christopher Benoit, who has been the CEO since incorporation. Alphazyme was acquired by Maravai Lifesciences Holdings, Inc. on February 22, 2023, for $145 million. | Commercial Services |
- Stock Market
- Insiders
- Chad Decker